Caroline Ven – CEO, pharma.be
pharma.be is the association of the Belgian R&D-based pharmaceutical industry, representing over 42,000 employees at 130 companies. CEO Caroline Ven outlines the crucial role that pharma.be and its members played…
Address: Terhulpsesteenweg one hundred sixty-six
1 170 Brussels ,Belgium
Tel: +32 2 661 91 03
pharma.be, the General Association of the Pharmaceutical Industry, currently groups 140 pharmaceutical companies with operations in Belgium. As a full partner of physicians, pharmacists, hospitals, governments and other stakeholders, it has a mission to promote better health through therapeutic innovation in the field of medicinal products for human use. A top priority is to ensure that Belgian patients can gain access to the ‘medicines of tomorrow’ arising from research and development as soon as possible.
Serving the interests of the pharmaceutical industry while taking into consideration all relavent stakeholders as well.
pharma.be is the association of the Belgian R&D-based pharmaceutical industry, representing over 42,000 employees at 130 companies. CEO Caroline Ven outlines the crucial role that pharma.be and its members played…
Mr Neels, can you please begin by introducing our readers to pharma.be and describe its key activities and vision? pharma.be is the General Association of the Pharmaceutical Industry in Belgium…
Thanks to its world-renowned networks of medical and academic institutions, the long-standing presence of Big Pharma, and a favourable regulatory environment, Belgium has a well-established tradition of excellence in clinical…
Belgium’s Flanders region is a hotbed of biotech excellence, with numerous examples of university spin-offs being translated into commercial-stage companies and many of those later acquired by Big Pharma. Wouter…
Nipro’s Serge Kemps explains how the COVID-19 pandemic and its after-effects led the Japanese-headquartered medtech firm to diversify its offering beyond its traditional area of focus, renal care, and establish…
Karel van de Sompel of GIBBIS – the pluralistic federation of the public and private social-profit healthcare sector within the Brussels area – outlines the scope and aims of the…
Benelux is a crucial cluster for Bristol Myers Squibb (BMS), which recently started construction of its first European CAR-T cell therapy production centre at the Leiden Bio Science Park. Sally…
Celltrion Healthcare Belgium’s Nicolas Van Gelder introduces the concept of ‘biobetters’ and how they differ from standard biosimilars and originator biologics, the reception and uptake of these products so far…
Accord Healthcare’s Stefano Christoffersen outlines the strategy that has led to Accord becoming one of the fastest-growing generics and biosimilar companies in Europe, why the firm has chosen to focus…
Ahead of the much-discussed implementation of an EU-wide legislative framework on joint clinical assessments in 2025, Merck’s Nikola Vesic outlines the scope and aims of the reform and highlights some…
Belgium is a key country for Sanofi in Europe as home to its Geel production site, in which almost EUR one billion has been invested over the past 15 years,…
Stephan Van Nieuwenhove of Finnish national champion Orion Pharma outlines the company’s entrance into the Benelux markets, the significance of the recent acquisition of Belgian animal health firm Inovet BV,…
Diane Kleinermans leads the reimbursement commission at Belgium’s medicines payer, the National Institute for Health and Disability Insurance (NIHDI). With Belgium currently undergoing a landmark reform of its reimbursement procedure,…
Alexander Alonso, GM of medtech giant BD’s Benelux affiliate explains the impact of the COVID-19 pandemic on its operations, the company’s 2025 strategy, and some of the most significant recent…
See our Cookie Privacy Policy Here
